• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[意大利儿童肺炎球菌疾病的疾病成本研究]

[Cost-of-illness study of pneumococcal disease in Italian children].

作者信息

Colombo G L

出版信息

Ann Ig. 2002 Sep-Oct;14(5):373-88.

PMID:12508446
Abstract

Streptococcus pneumoniae (S pneumoniae, or pneumococcus) is a leading cause of illness in children, and causes illness and death among the elderly and persons with certain underlying conditions. A Cost-of-Illness (COI) estimate for each pneumococcal disease (meningitis, bacteremia, pneumonia, and otitis media) was determined using decision tree analysis that considered both direct and indirect costs. Information on the burden of pneumococcal disease in Italy, in terms of data on the incidence and seroprevalence of disease was collected from published and unpublished records, supplemented, and verified by Italian pediatric and infectious disease experts. The annual cost to society of caring for children with pneumococcal disease is estimated to be around 59,604,477 euro including both direct costs and indirect costs (productivity changes). Direct costs accounted for 39.9% of the total costs. The value of resources used to treat otitis media was 60.6% of the total direct costs; 31.9% was the value of resources for treating pneumonia; 6.5% for treating bacteremia; 1.0% for treating meningitis. A sensitivity analysis confirmed the robustness of the results.

摘要

肺炎链球菌(肺炎链球菌,或肺炎球菌)是儿童患病的主要原因,并且在老年人和患有某些基础疾病的人群中导致疾病和死亡。使用考虑了直接和间接成本的决策树分析确定了每种肺炎球菌疾病(脑膜炎、菌血症、肺炎和中耳炎)的疾病成本(COI)估计值。关于意大利肺炎球菌疾病负担的信息,根据疾病发病率和血清阳性率的数据,从已发表和未发表的记录中收集,并由意大利儿科和传染病专家进行补充和核实。照顾患有肺炎球菌疾病儿童的社会年度成本估计约为59,604,477欧元,包括直接成本和间接成本(生产力变化)。直接成本占总成本的39.9%。用于治疗中耳炎的资源价值占总直接成本的60.6%;用于治疗肺炎的资源价值占31.9%;用于治疗菌血症的资源价值占6.5%;用于治疗脑膜炎的资源价值占1.0%。敏感性分析证实了结果的稳健性。

相似文献

1
[Cost-of-illness study of pneumococcal disease in Italian children].[意大利儿童肺炎球菌疾病的疾病成本研究]
Ann Ig. 2002 Sep-Oct;14(5):373-88.
2
The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.瑞典小儿肺炎球菌疾病的成本负担以及使用7价肺炎球菌疫苗预防的潜在成本效益。
Vaccine. 2009 Mar 4;27(10):1601-8. doi: 10.1016/j.vaccine.2008.12.033. Epub 2009 Jan 13.
3
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.瑞士 13 价肺炎球菌结合疫苗的成本效益分析。
Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028. Epub 2012 Apr 20.
4
Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.瑞典使用7价肺炎球菌结合疫苗(PCV-7)的全民疫苗接种计划的成本效益分析。
Scand J Infect Dis. 2008;40(9):721-9. doi: 10.1080/00365540802014872.
5
[Economic cost of Streptococcus pneumoniae community-acquired pneumonia, meningitis and bacteremia in an adult population that required hospitalization in Bogotá, Colombia].[哥伦比亚波哥大成年人群中因肺炎链球菌引起的社区获得性肺炎、脑膜炎和菌血症需住院治疗的经济成本]
Biomedica. 2014 Jan-Mar;34(1):92-101. doi: 10.1590/S0120-41572014000100012.
6
Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.儿童肺炎球菌性中耳炎和肺炎疫苗接种:效益与成本分析
Am J Manag Care. 2000 Jul;6(10 Suppl):S526-35.
7
Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente.评估凯撒医疗集团内部肺炎球菌疾病及疫苗接种的成本和成本效益。
Vaccine. 2000 Dec 8;19 Suppl 1:S83-6. doi: 10.1016/s0264-410x(00)00284-x.
8
Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.孟加拉国农村地区儿童侵袭性肺炎球菌疾病:基于人群监测的结果
Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S103-13. doi: 10.1086/596543.
9
Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.香港地区可通过7价肺炎球菌结合疫苗预防的肺炎球菌疾病导致的儿科住院情况。
Vaccine. 2007 Sep 28;25(39-40):6837-41. doi: 10.1016/j.vaccine.2007.07.039. Epub 2007 Aug 7.
10
Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.在挪威儿童疫苗接种计划中添加7价肺炎球菌结合疫苗(PCV - 7)的成本效益。
Vaccine. 2006 Jul 17;24(29-30):5690-9. doi: 10.1016/j.vaccine.2006.04.042. Epub 2006 May 5.